Forget Rocket Lab: This Aerospace Defense Titan Is a Far Smarter Valuation Play

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • GD trades at 21x earnings on $54 billion in revenue, yet commands nearly the same market cap as unprofitable RKLB at 115x sales.

  • General Dynamics returned over $2 billion to shareholders through dividends and buybacks while Rocket Lab raised $450 million selling new shares to fund operations.

  • General Dynamics holds $188 billion in contract backlog and trades $49 below Wall Street's average target, capturing defense tailwinds without speculative risk.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and General Dynamics didn't make the cut. Grab the names FREE today.

Forget Rocket Lab: This Aerospace Defense Titan Is a Far Smarter Valuation Play

© 3DSculptor / iStock via Getty Images

Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) is the ticker everyone wants to talk about, riding a 425.79% one-year run on Neutron hype, Golden Dome contracts, and the coming wave of space-economy IPOs. Beneath that one-year run sit operating realities the hype obscures.

Rocket Lab carries a $78.58 billion market cap on $679.5 million in trailing revenue, a 115.64 price-to-sales ratio, and a -26.9% profit margin. The Neutron rocket debut was pushed from Q1 2026 to Q4 2026 after a stage-1 tank test failure, the company burned $165.5 million in operating cash in FY 2025, and management raised $450 million through an at-the-market equity offering in a single quarter. Diluted share count has marched to 629 million. This is a story stock priced for a future that has not arrived, in a launch business that is, as the custom thesis puts it, capital-intensive, carrying extreme execution risks and thin operating margins where a single mechanical anomaly can halt revenues for quarters.

Now look at General Dynamics (NYSE:GD), which carries a $92.73 billion market cap, barely larger than Rocket Lab, while running an entirely different business.

1. The Valuation Mismatch Is Absurd

General Dynamics trades at 21x trailing earnings and 21x forward earnings on $53.81 billion in trailing revenue and $15.88 in trailing EPS. Rocket Lab generates roughly 1% of that revenue at a $78.58 billion cap. The market is paying nearly the same dollar amount for a profitable defense titan with a 0.345 beta as it is for an unprofitable small-launch operator with a 2.313 beta. Year-to-date, General Dynamics is up 2.75% while Rocket Lab is up 94.61%. The crowd has chosen sides.

2. A Cash Machine Returning Billions In Capital

Q1 FY26 operating cash flow hit $2.155 billion, or 192% of net earnings, with free cash flow of $1.952 billion. FY25 produced $5.12 billion in operating cash flow and $3.96 billion in free cash flow. Capital returned: $1.593 billion in FY25 dividends plus $637 million in buybacks, with another $405 million in Q1 dividends and $217 million in repurchases. The dividend per share sits at $6.09. Rocket Lab pays no dividend and funds growth by selling stock.

3. The Same Tailwinds, Already Monetized

Total estimated contract value reached $188.44 billion against a consolidated 2-to-1 book-to-bill ratio. Marine Systems revenue grew 21.0% with operating earnings up 26.4%, anchored by the company’s role as the exclusive builder of the U.S. Navy’s nuclear-powered submarines. Gulfstream delivered 38 aircraft with the Aerospace book-to-bill swinging to 1.2x from 0.8x. CEO Phebe Novakovic called it “a very good start to the year, delivering strong operating results and excellent cash conversion.” Four consecutive quarters of EPS beats back her up.

Wall Street’s average target sits at $391.55 against a current $342.89. For investors weighing speculative space exposure against established defense cash flow, the data sits on the table: a 115x price-to-sales small-launch operator on one side, a 21x earnings prime contractor returning billions in capital on the other.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

KMX Vol: 4,551,778
GLW Vol: 12,647,763
INTC Vol: 154,551,928
KLA
KLAC Vol: 9,445,151
SMCI Vol: 53,111,643

Top Losing Stocks

ACN Vol: 27,854,516
EPAM Vol: 3,156,832
CTSH Vol: 20,891,552
CTRA Vol: 73,319,495
KR Vol: 15,136,830